文献速递核素与放射性配体治疗肿瘤 PET/CT

晚期神经内分泌肿瘤多周期177Lu-DOTA-EB-TATE肽受体放射性核素治疗

Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE.
PubMed 文献 · J Nucl Med · 2020-08-21

结果显示治疗耐受良好,无CTCAE 4级不良事件,1.89和3.97 GBq/周期组肿瘤控制效果优于1.17 GBq/周期组。

要点

  • 177Lu-DOTA-EB-TATE剂量递增至3.97 GBq/周期耐受良好,无4级不良事件。
  • 1.89和3.97 GBq/周期组肿瘤控制率高于1.17 GBq/周期组。
  • 3级血液学毒性见于B组1例和C组3例,无肾毒性。

核心结论

  • 177Lu-DOTA-EB-TATE剂量递增至3.97 GBq/周期耐受良好,1.89和3.97 GBq/周期剂量在肿瘤控制方面有效且优于1.17 GBq/周期。

主要发现

  • 治疗耐受良好,无CTCAE 4级危及生命的不良事件。
  • CTCAE 3级血液学毒性:B组1例(16.6%)血小板减少,C组3例(21.4%)血小板减少3例、贫血1例。
  • CTCAE 3级肝毒性(天冬氨酸氨基转移酶升高):A组1例(8.3%),C组1例(7.1%);未观察到肾毒性。
  • 按EORTC标准,A、B、C组总体疾病缓解率分别为50.0%、50.0%、42.9%;总体疾病控制率B组83.3%、C组71.5%高于A组66.7%。
  • 按修改版PERCIST,疾病缓解率较低但疾病控制率相似;基线SUVmax 15–40时,首次PRRT后SUVmax变化百分比A组+2.1%±40.8%,B组-38.7%±10.0%,C组-14.7%±20.0%(P=0.001);第三次PRRT后三组均下降(A组-6.9%±42.3%,B组-49.2%±30.9%,C组-11.9%±37.9%,P=0.044)。

关键数值与推荐

  • 不良事件按CTCAE 5.0版分级,治疗反应按EORTC标准和修改版PERCIST评估。
  • EORTC标准总体疾病缓解率:A组50.0%、B组50.0%、C组42.9%;总体疾病控制率:A组66.7%、B组83.3%、C组71.5%。
  • 基线SUVmax 15–40亚组首次PRRT后SUVmax变化百分比组间比较P=0.001,第三次PRRT后P=0.044。

临床怎么用

  • 晚期神经内分泌肿瘤可考虑177Lu-DOTA-EB-TATE多周期治疗,剂量递增至3.97 GBq/周期耐受良好。
  • 1.89和3.97 GBq/周期在肿瘤控制方面优于1.17 GBq/周期,但需关注血液学毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to evaluate the safety and efficacy of multiple cycles of 177Lu-DOTA-Evans blue (EB)-TATE peptide receptor radionuclide therapy (PRRT) at escalating doses in neuroendocrine tumors (NETs). Methods: Thirty-two NET patients were randomly divided into 3 groups and treated with escalating doses. Group A received 1.17 ± 0.09 GBq/cycle; group B, 1.89 ± 0.53 GBq/cycle; and group C, 3.97 ± 0.84 GBq/cycle. The treatment was planned for up to 3 cycles. Treatment-related adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Treatment response was evaluated according to the European Organisation for Research and Treatment of Cancer criteria and modified PERCIST. Results: Administration of PRRT was well tolerated, without life-threatening adverse events (CTCAE grade 4). CTCAE grade 3 hematotoxicity was recorded in 1 patient (16.6%) in group B (thrombocytopenia) and 3 patients (21.4%) in group C (thrombocytopenia in 3, anemia in 1). CTCAE grade 3 hepatotoxicity (elevated aspartate aminotransferase) was recorded in 1 patient in group A (8.3%) and 1 patient in group C (7.1%). No nephrotoxicity was observed. According to the criteria of the European Organisation for Research and Treatment of Cancer, the overall disease response rates were similar in groups A, B, and C (50.0%, 50.0%, and 42.9%, respectively), and the overall disease control rates were higher in groups B (83.3%) and C (71.5%) than in group A (66.7%). According to modified PERCIST, a lower disease response rate but a similar disease control rate were found. When a comparable baseline SUVmax ranging from 15 to 40 was selected, the percentage change in SUVmax increased slightly in group A (2.1% ± 40.8%) but decreased significantly in groups B and C (-38.7% ± 10.0% and -14.7% ± 20.0%, respectively) after the first PRRT (P = 0.001) and decreased in all 3 groups after the third PRRT (groups A, B, and C: -6.9% ± 42.3%, -49.2% ± 30.9%, -11.9% ± 37.9%, respectively; P = 0.044). Conclusion: Dose escalations of up to 3.97 GBq/cycle seem to be well tolerated for 177Lu-DOTA-EB-TATE. 177Lu-DOTA-EB-TATE doses of 1.89 and 3.97 GBq/cycle were effective in tumor control and more effective than 1.17 GBq/cycle.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Liu Q, Zang J, Sui H, et al. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE. J Nucl Med. 2020. PMID: 32826319. doi:10.2967/jnumed.120.248658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。